Alzheimer's Disease: Drugs
The question
To ask the Secretary of State for Health and Social Care, if he will publish the cost-benefit modelling for the prescription of (a) donanemab and (b) lecanemab for patients with early-stage Alzheimer’s disease.
Answered by Karin Smyth
The National Institute for Health and Care Excellence has published the company’s evidence submission, which includes the company’s evidence on costs and benefits, and the external assessment group report, which assesses the company’s evidence submission as part of the papers that were considered by the independent Appraisal Committee. Information that is commercially confidential has been redacted.
The economic models themselves cannot be published because they contain commercially confidential information. The papers for lecanemab are available at the following link:
https://www.nice.org.uk/guidance/indevelopment/gid-ta11220/documents
In addition, the papers for donanemab are available at the following link:
https://www.nice.org.uk/guidance/indevelopment/gid-ta11221/documents.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →